How Honest Supplement Brands Get Caught in the FDA's Spiking Crackdown

Spiking, the practice of secretly adding undeclared prescription drug ingredients to dietary supplements, is one of the FDA's most aggressive enforcement priorities in 2026. Recent recalls and public health alerts have named brands across the supplement industry, including Primal Herbs (undeclared sildenafil), GURU INC's Infla-650 capsules (hidden drug ingredients), and FAonline's ForeverMen capsules (undeclared prescription drugs).

The reputational damage from a spiking allegation is catastrophic, and the legal exposure can extend beyond the company that intentionally added the drug. Honest supplement brands sourcing finished products, blends, or raw materials from third parties can find themselves swept into FDA enforcement actions if their suppliers, contract manufacturers, or co-packers introduced undeclared pharmaceutical ingredients into the supply chain.

Brand protection in the dietary supplement industry is no longer a marketing concept. It is a legal and supply chain discipline that requires deliberate effort across every relationship a brand maintains.

How Spiking Happens to Brands That Did Not Intend to Spike

Most supplement brands do not intentionally adulterate their products. The risk arises through the supply chain. A brand can become legally and reputationally exposed in several ways:

•        A contract manufacturer uses raw materials sourced from a supplier that adulterated an ingredient with an undeclared pharmaceutical.

•        A botanical extract supplier substitutes a cheaper or less effective ingredient with a synthetic compound that produces the marketed effect.

•        A co-packer runs a brand's product on shared equipment that was not properly cleaned after producing a different product containing undisclosed ingredients.

•        A turnkey supplement product is purchased from a manufacturer that secretly spikes its formulas to deliver claimed effects.

In each scenario, the brand on the label is the one named in the FDA recall notice. The brand's reputation, retailer relationships, and customer trust are damaged regardless of where the contamination originated.

The 2026 Enforcement Pattern: Three Risk Categories

FDA Warning Letter analysis from 2025 and early 2026 reveals a consistent pattern in supplement enforcement. The agency is concentrating on three risk categories:

1.     Undisclosed pharmaceutical ingredients (spiking). The most concerning trend. Sexual enhancement, weight loss, sports performance, and pain relief categories are receiving the highest scrutiny. Common hidden ingredients include sildenafil, tadalafil, sibutramine, phenolphthalein, and various synthetic steroids.

2.     Microbial contamination. Salmonella and E. coli contamination tied to poor sourcing of raw plant materials and inadequate manufacturing sanitation.

3.     Dosage and ingredient inaccuracies. Products that contain less of the active ingredient than the label claims, or contain ingredients not disclosed on the Supplement Facts panel.

The Legal Exposure for Brands

When a supplement is found to contain an undeclared pharmaceutical ingredient, the FDA classifies it as an unapproved new drug, an adulterated product, and a misbranded product. Each of these classifications triggers separate enforcement authorities under the Federal Food, Drug, and Cosmetic Act.

Consequences can include:

Enforcement Tool	What It Means	Typical Brand Impact
Public health alert	FDA notifies the public not to consume the product	Immediate retailer pulls, customer refund demands
Voluntary or mandatory recall	Removal of product from commerce	Inventory loss, recall logistics costs, brand damage
Warning Letter	Public document citing violations	Reputational damage, retailer compliance demands
Seizure or injunction	Court action to halt distribution	Operational shutdown, significant legal costs
Criminal prosecution	DOJ action for intentional violations	Personal liability, prison exposure for executives

The Brand Protection Framework: Five Controls Every Supplement Brand Needs

Honest brands cannot prevent every supplier from acting in bad faith, but they can implement controls that dramatically reduce exposure and demonstrate due diligence in the event of an FDA action.

1.     Supplier qualification with verification of authorization status. Every raw material supplier and contract manufacturer should be qualified through documented due diligence. This includes facility audits, review of cGMP compliance history, verification of FDA registration status, and review of any prior Warning Letters or Form 483 observations.

2.     Identity testing on every incoming raw material. Identity testing under 21 CFR 111 is a regulatory requirement for dietary supplement manufacturers, but many brands rely entirely on supplier certificates of analysis. Independent identity testing on every lot of incoming raw material is the strongest defense against adulteration entering the supply chain.

3.     Third-party finished product testing. USP, NSF, and ConsumerLab certifications verify that finished products contain what the label claims and do not contain undeclared substances. While voluntary, third-party certifications create a documented compliance record and demonstrate good faith to regulators.

4.     Contract terms that allocate liability and require compliance attestations. Contracts with contract manufacturers, raw material suppliers, and co-packers should include explicit cGMP compliance representations, indemnification provisions, audit rights, and the right to require third-party testing. Brands without these contract terms have limited recourse when a supplier fails.

5.     Ongoing supplier monitoring. Initial qualification is not enough. Brands should review supplier compliance history annually, monitor FDA Warning Letter databases for actions against their suppliers, and track recall events in the supplement industry that may implicate shared suppliers.

If Your Brand Receives a Warning Letter or Notice of Action

Speed and strategy matter. The FDA typically requires a response within 15 working days. A weak or generic response can escalate the matter to product seizure, injunction, or criminal referral. A well-crafted response demonstrates corrective action, addresses each cited violation specifically, and establishes the brand's commitment to ongoing compliance.

Brands should not draft Warning Letter responses without specialized FDA legal counsel. The response is a public document and becomes part of the regulatory record for the brand. The cost of a properly crafted response is a small fraction of the cost of an enforcement escalation.

How Bustos Law Group Protects Supplement Brands

Bustos Law Group provides comprehensive FDA legal services for dietary supplement brands, including supplier qualification reviews, contract drafting and negotiation, label and ingredient reviews, Warning Letter response strategy, and recall management.

With a 95% Warning Letter resolution rate and a dedicated team of food and supplement experts, the firm helps honest brands implement the legal infrastructure they need to protect themselves from supply chain risks they did not create.

Spiking is not going away. The FDA's enforcement appetite is not shrinking. Schedule a consultation with Bustos Law Group to review your brand protection framework before a supplier failure becomes your problem.